We would like to inform you that our subsidiary, Gyre Therapeutics, has also issued a press release regarding the research paper on F351 that we introduced on May 30th.
The comments of Dr. Han-In, CEO of Gyre Therapeutics, are featured in it.
For more information, please refer to the following.
Gyre Therapeutics F351に関する研究論文についてのプレスリリース
Press Release on Research Paper Regarding Gyre Therapeutics F351.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.